This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eugster, E. A. Articles by Pescovitz, O. H. Search for Related Content PubMed PubMed Citation Articles by Eugster, E. A. Articles by Pescovitz, O. H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Gigantism

Section of Pediatric Endocrinology/Diabetology, Department of Pediatrics, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana 46202-5225

Address correspondence and requests for reprints to: Erica A. Eugster, M.D., Assistant Clinical Professor of Pediatrics, Pediatric Endocrinology/Diabetology, Riley Hospital #5984, 702 Barnhill Drive, Indianapolis, Indiana 46254. E-mail: eeugster{at}iupui.edu

	Introduction

Top Introduction Etiologies of Gigantism Consequences of Prolonged GH... Clinical Aspects of Gigantism Treatment of Gigantism Conclusion References

 
FROM ANCIENT history throughout the modern age, individuals of extraordinary physical proportions have figured prominently in myths and tales of magic. The concept of superhuman size, whether in the form of Goliath, Hercules, or Bigfoot, has consistently inspired a sense of awe and enthrallment. No less intriguing are the well-documented cases of true gigantism, including that of Robert Wadlow (The Alton Giant) who, at 8 feet 11 inches (272 cm) at his death, remains the tallest person ever recorded (1), and that of SA (Fig. 1), the current tallest living woman at 7 feet 5.5 inches (227 cm). In recent years, scientific breakthroughs regarding the molecular genetic, histologic, and hormonal basis of GH excess have enhanced our understanding of this inherently fascinating disease and have provided important insights into its pathogenesis, prognosis, and the potential for therapeutic intervention.

View larger version (116K): [in this window] [in a new window]   Figure 1. SA, the tallest living woman, standing with one of the authors (EAE).

	Etiologies of Gigantism

Top Introduction Etiologies of Gigantism Consequences of Prolonged GH... Clinical Aspects of Gigantism Treatment of Gigantism Conclusion References

 
Excessive GH secretion has several potential causes and may occur in the context of a number of heterogeneous disorders. Among these, a variety of specific pathophysiologic mechanisms have been elucidated or proposed, all of which result in GH excess as the final common abnormality. Cases of GH hypersecretion may be subdivided into two main categories: those originating from a primary pituitary source and those that seem to be caused by increased GHRH secretion or dysregulation. A spectrum of pathologic pituitary morphology exists, ranging from isolated pituitary adenomas typically seen in cases of primary pituitary GH hypersecretion to pituitary hyperplasia, which is usually found in the context of prolonged GHRH excess. Although gigantism typically occurs as an isolated disorder, it may also be a feature of an underlying medical condition such as multiple endocrine neoplasia (MEN) type-1, McCune-Albright syndrome (MAS), neurofibromatosis, or Carney complex. The various etiologies of GH excess along with their associated characteristics are summarized in Table 1 and discussed further.

Many cases of gigantism result from primary GH secretion by pituitary tumors comprised of somatotrophs (GH-secreting cells) or mammosomatotrophs (GH and PRL-secreting cells), either in the form of a pituitary microadenoma or, rarely, macroadenoma (6). The relative contributions of inherent pituitary defects vs. hypothalamic factors in the pathogenesis of pituitary tumors are far from resolved, however. The monoclonal nature of most pituitary adenomas (8), confirmed by X-inactivation studies, has implied that they originate from a single altered cell. The concept of an intrinsic pituitary defect is further supported by the discovery that specific molecular genetic abnormalities seem to form the basis of GH hypersecretion in many cases. In contrast, evidence also exists to suggest an important role for GHRH in disease progression because the number of GHRH messenger RNA transcripts within pituitary adenomas correlates strongly with their clinical behavior (9). The exact functional consequence of locally produced GHRH remains to be clarified, although an autocrine or paracrine role has been suggested by the finding of an elevated plasma GHRH concentration in association with a pituitary somatotroph adenoma, which normalized following surgical removal of the adenoma (10). An approach that integrates the different theories of pituitary adenoma formation has recently been proposed, in which tumor growth ensues via a multistep process. In this model, the initial event consists of genetic transformation of cells, with abnormal growth being subsequently promoted by hypophysiotrophic hormones and other growth factors (11). Identified molecular genetic abnormalities implicated in the pathogenesis of primary pituitary GH excess are discussed below.

Gs mutations

The heterotrimeric G-proteins play an integral role in postligand signal transduction in many endocrine cells, in which they act by stimulating adenylyl cyclase, resulting in cAMP accumulation and subsequent gene transcription. Activating point mutations of the G-protein stimulatory subunit Gs are known to form the basis for McCune-Albright syndrome (MAS), a rare disorder characterized by the classic triad of precocious puberty, café au lait spots, and fibrous dysplasia of bone (12). "Constitutive activation" refers to the autonomous and uncontrolled activation of G-protein-mediated cAMP formation that occurs in MAS, resulting in hyperfunction of endocrine and nonendocrine tissues. In some patients with MAS, endocrine abnormalities include gigantism caused by the development of pituitary mammosomatotroph adenomas or hyperplasia. The reported point mutations observed in multiple affected tissues of patients with MAS (13), including those with gigantism (14), involve a single amino acid substitution within codon 201 (exon 8) or codon 227 (exon 9) of the Gs gene. Interestingly, these same mutations have also been identified in somatotrophs of up to 40% of sporadic GH-secreting pituitary adenomas (15). The resulting oncogene, gsp, is thought to induce tumorigenesis by virtue of persistent activation of adenylyl cyclase with subsequent GH hypersecretion (16). In contrast to tumors without such mutations, gsp-containing pituitary adenomas tend to be smaller, with morphologic characteristics suggestive of slow growth, despite an absence of detectable differences in disease progression between the two groups.

Allelic deletion of the 11q13 locus

Loss of heterozygosity (LOH) at the site of a putative tumor suppressor gene located on chromosome 11q13 represents another molecular genetic abnormality, whose association with pituitary GH excess has been firmly established. First identified within tumors from patients with MEN-1 (17), the genetic mutation was originally believed to be related to the MEN-1 gene and was thought to be the cause of the GH excess in this disease. The recent cloning of the MEN-1 gene, however, has led to the revelation that the affected locus codes for a product that is distinct from the MEN-1 gene. This has been demonstrated by the finding of an intact MEN-1 sequence in individuals from two unrelated kindreds with familial acromegaly/gigantism and 11q13 LOH (18). In addition to familial non-MEN acromegaly/gigantism (19), LOH at 11q13 has also been observed in all types of sporadically occurring pituitary adenomas (20). The exact nature of the encoded product and its role in tumor formation have yet to be clarified. Of note is the fact that LOH at 11q13 and other loci within pituitary adenomas has been correlated with an increased propensity for tumor invasiveness and biological activity (21).

Additional theoretical intrinsic pituitary defects leading to abnormal cell proliferation and excessive GH secretion might result from abnormal activation of the GHRH receptor, somatostatin receptor, pituitary transcription factors, or other growth-related signal peptides. As information regarding the complex developmental cascade of pituitary ontogenesis continues to accumulate, new light will undoubtedly be shed on the underlying mechanisms of both normal and abnormal pituitary cell growth.

Secondary GH excess

Causes of secondary GH excess include those in which there is increased secretion of hypothalamic GHRH, either from an intracranial or ectopic source, and those in which abnormal regulation of the hypothalamic-pituitary GH axis has occurred. Secondary GH excess represents an important, if poorly understood, cause of gigantism. Advances in biochemical detection assays and molecular genetic characterization should allow improved localization of the underlying hormonal abnormality in these cases.

GHRH excess

Hypothalamic GHRH excess or dysregulation has been postulated to be the most common cause of GH hypersecretion in the pediatric population. Although not definitively proven, clinical cases that support this hypothesis include congenital gigantism with massive diffuse pituitary hyperplasia, in which biochemical studies suggested central GHRH hypersecretion (5), as well as a case of mammosomatotroph hyperplasia in which systemic GHRH concentrations were found to be normal (4). The involvement of mammosomatotrophs, frequently a feature of GH excess originating in childhood (22), is further suggestive of early onset increased GHRH exposure because this cell type predominates in fetal life but is rare in the adult. Despite this evidence, the underlying mechanism of the putative abnormality in GHRH action in these cases remains unknown. Theoretical possibilities include an activating mutation in hypothalamic GHRH neurons or a decrease in somatostatin tone (see below). Another form of intracranial GHRH excess occurs in the setting of a neural tumor, such as a gangliocytoma (23, 24) or neurocytoma (25), arising within or in close proximity to the sella. Prolonged tumor secretion of GHRH leads to pituitary hyperplasia with or without adenomatous transformation, resulting in increased levels of GH and other adenohypophyseal peptides. Electron microscopy in such cases has revealed intimate contact between neurons of the tumor and pituitary GH-secreting cells (23). GHRH excess may also originate from an extracranial and ectopic neoplastic source, which represents a well-recognized cause of acromegaly (26), but has only rarely been implicated in cases of GH excess in children (3). Ectopic GHRH-secreting tumors have included carcinoid, pancreatic islet cell, and bronchial neoplasms. Recently, the first reported case of ectopic GH as the cause of acromegaly was identified, in which tumor cells from a malignant lymphoma were found to secrete high levels of pituitary GH (27).

Abnormal Somatostatin tone

Secondary GH excess may also occur from disruption of somatostatin tone. Tumor infiltration into somatostatinergic pathways has been hypothesized to form the basis for GH excess in rare cases of gigantism associated with neurofibromatosis and optic gliomas or astrocytomas (28, 29). Immunocytochemical studies in this setting have demonstrated interruption of somatostatinergic neurons, whereas neuroimaging has revealed diminished magnetic resonance signal intensity in somatostatin-rich areas of the brain (30).

	Consequences of Prolonged GH Excess

Top Introduction Etiologies of Gigantism Consequences of Prolonged GH... Clinical Aspects of Gigantism Treatment of Gigantism Conclusion References

 
Transgenic mice models with targeted overexpression of GH, GHRH, and insulin-like growth factor (IGF)-I have provided invaluable tools for the exploration of the pathogenetic mechanisms underlying the physiological effects of chronic GH exposure. The first such model, constructed by fusion of the mouse metallothionein-1 gene promoter to the rat GH gene (31), resulted in dramatically accelerated growth in transgenics as compared with control littermates, along with greatly increased circulating GH and tissue GH messenger RNA levels. Subsequently, the role of elevated GHRH in GH hypersecretion was demonstrated by the finding of pituitary hyperplasia and adenomas, increased somatic growth, and elevated plasma GH levels in transgenic mice overexpressing human GHRH (32). The differential effects of chronic GH exposure vs. IGF-I excess have been further investigated by comparing changes exhibited by animals with isolated overexpression of IGF-I with those observed in animals overexpressing GH or GHRH. Anatomical and biochemical changes found to be unique to animals with chronically elevated GH levels have included renal and hepatic enlargement, glomerulosclerosis, skin abnormalities, and elevations of insulin and cholesterol (33). In line with the diverse clinical symptomatology observed in patients with acromegaly, these studies also emphasize the fact that excessive GH exposure has an impact on all tissues in the body.

	Clinical Aspects of Gigantism

Top Introduction Etiologies of Gigantism Consequences of Prolonged GH... Clinical Aspects of Gigantism Treatment of Gigantism Conclusion References

 
Unlike GH excess beginning in adulthood, in which an insidious onset and delayed diagnosis are the norm, the presentation of gigantism is usually quite dramatic and the diagnosis is fairly straightforward. The cardinal clinical feature of gigantism is growth acceleration. All growth parameters are affected, although not necessarily symmetrically because mild to moderate obesity is common and macrocephaly has been noted to precede linear and weight acceleration in at least one case (34). Due to the small number of affected patients, there are no precise figures regarding the prevalence of other signs and symptoms of GH excess in children with gigantism. However, a review of clinical case reports reveals several common features among such patients. All have been noted to have coarse facial features and disproportionately large hands and feet with thick fingers and toes. Frontal bossing and a prominent jaw have frequently been present. Organomegaly and deteriorating glucose tolerance were also documented in one patient observed over several years before treatment (29).

In contrast, the myriad signs and symptoms of prolonged GH excess in adults with acromegaly have been well described (35). Enlargement of facial features, excess acral growth and soft tissue swelling are essentially ubiquitous among these patients. Additional common manifestations include headaches, excessive sweating, peripheral neuropathy and arthritis. Frequently associated endocrinopathies include hypogonadism, diabetes, thyromegaly, and galactorrhea. The most common cause of death in acromegaly is from cardiovascular disease (36). Recent observations regarding other consequences of GH toxicity include a potential role for GH in normal and abnormal erythropoiesis (37) and in the pathogenesis of retinopathy (38).

Physical examination of the child presenting with growth acceleration must include a search for evidence of other etiologies of increased growth velocity, such as excessive sex steroid levels, as well as careful attention to the presence of additional physical findings that might suggest an underlying disorder, such as multiple café au lait spots. The differential diagnosis of growth acceleration is contained in Table 2.

Laboratory findings

An elevated IGF-I on initial screening is suggestive of GH excess, as an excellent linear dose-response correlation between plasma IGF-1 levels and 24-h mean GH secretion have been demonstrated (39). Potential confusion may arise when evaluating normal adolescents because significantly higher IGF-I levels occur during puberty than in adulthood (40), a fact that emphasizes the importance of using age-referenced norms. Although higher concentrations of IGF-I have been reported in children and adolescents with constitutional tall stature (41), no significant differences in neurosecretory dynamics of the GH-IGF-I axis have been found in healthy young adults with heights of more than three SD above the mean as compared with controls (42). The gold standard for making the diagnosis of GH excess is a failure to suppress serum GH levels to less than 5 ng/dL after a 1.75 gm/kg oral glucose challenge (maximum, 75 g). Hyperprolactinemia is an almost invariable finding in GH excess presenting in childhood, undoubtedly related to the fact that mammosomatotrophs are by far the most common type of GH-secreting cells involved in childhood gigantism. The coexistence of both GH and PRL has been clearly demonstrated within the secretory granules contained in the cytoplasm of these cells (22). Although not necessary to make the diagnosis, GH response to additional stimuli such as TRH testing is typically paradoxical. Measurement of serum GHRH levels are useful in differentiating ectopic GHRH excess from other causes of GH hypersecretion. Imaging by magnetic resonance imaging or computed tomography is an essential step in the evaluation following biochemical detection of GH excess.

Psychological aspects of tall stature/gigantism

One need only review the striking positive correlation between stature and financial/professional success in our society to be convinced that "heightism" is a true phenomenon. However, when present to an extreme degree, tallness ceases to be an advantage and may be perceived as a burden, resulting in both physical, as well as psychological, handicaps. This has prompted the pharmacological treatment of constitutionally tall adolescents with sex steroids to accelerate epiphyseal fusion, a practice that has been in existence since the 1950s (43). Whereas tall girls, in particular, often report teasing and social difficulties as a result of their size, these problems generally disappear in adulthood, when the majority of normal tall men and women indicate satisfaction with their stature (44). Because no convincing data indicating lifelong psychopathology as a result of tall stature exists (45), it may be reasonable to pursue counseling as the initial treatment of choice for otherwise healthy tall adolescents with psychosocial difficulties related to their height. In contrast, pathologic tall stature as a result of GH excess obviously results in heights that are far beyond those observed in constitutionally tall individuals. Although no in-depth information regarding the psychological profile of patients with gigantism is available, case series indicate a high incidence of severe depression, social withdrawal, and low self-esteem (3).

	Treatment of Gigantism

Top Introduction Etiologies of Gigantism Consequences of Prolonged GH... Clinical Aspects of Gigantism Treatment of Gigantism Conclusion References

 
Several therapeutic modalities have been used in the treatment of GH hypersecretion. The optimal therapy in any given case is dictated by the characteristics of the GH-secreting lesion and other coexisting factors. For well-circumscribed pituitary adenomas, transsphenoidal surgery is the treatment of choice and may be curative (46). Radiation therapy, used as adjunctive or primary treatment, has also been moderately successful in inducing normalization of growth hormone levels (47). Major disadvantages to the use of irradiation exist, however, in the form of delayed efficacy in reducing GH levels and a high incidence of hypopituitarism following treatment.

The greatest progress in recent years in the treatment of GH excess has been within the realm of medical therapy. The development of somatostatin analogs, such as octreotide, represented a major addition to the pharmacological armamentarium for GH hypersecretion. Therapeutic response to octreotide, found to be highly effective in the majority of patients with gigantism or acromegaly, may be predicted by the decrement in serum GH levels after one sc dose (48). The new sustained-release somatostatin analog preparation lanreotide given in the form of an im injection every 2 weeks, has also been shown to be successful in returning GH levels to normal in acromegalic adults with pituitary adenomas (49) as well as in those with ectopic GHRH secretion (50). Although this drug is as yet untested in children, the improved dosing schedule of lanreotide clearly represents a potentially major advance in the treatment of gigantism and disorders of glucose homeostasis in pediatric patients. Side effects of somatostatin analogues consist mainly of mild transient gastrointestinal complaints and an increased risk of gallstones. Additional pharmacological therapy consists of the dopamine agonist bromocriptine, which can provide adjuvant medical treatment of gigantism and has been found to be safe when used in a child for an extended period of time (51). An exciting new therapeutic agent has recently emerged in the form of a competitive GHRH antagonist, which has been shown to effectively suppress GH and IGF-I levels in patients with acromegaly from pituitary somatotrophic tumors as well as ectopic GHRH hypersecretion (52, 53).

	Conclusion

Top Introduction Etiologies of Gigantism Consequences of Prolonged GH... Clinical Aspects of Gigantism Treatment of Gigantism Conclusion References

 
In summary, our current understanding of GH excess represents the end result of a unique blend of multidisciplinary investigation. Further illumination regarding the unexplained aspects of this interesting disease undoubtedly will occur as collaborative efforts continue into the new century.

Revised September 28, 1999.

Accepted September 28, 1999.

	References

Top Introduction Etiologies of Gigantism Consequences of Prolonged GH... Clinical Aspects of Gigantism Treatment of Gigantism Conclusion References

 

1. Behrens LH, Barr DP. 1932 Hypopituitarism beginning in infancy: the Alton giant. Endocrinology. 16:120–128.[Abstract/Free Full Text]
2. Sotos JF. 1996 Overgrowth, section II. Clin Pediatr.35(11):579–590.
3. Whitehead EM, Shalet SM, Davies D, Enoch BA, Price DA, Beardwell CG. 1982 Pituitary gigantism: a disabling condition. Clin Endocrinol. 17:271–277.[Medline]
4. Moran A, Asa SL, Kovacs K, et al. 1990 Gigantism due to pituitary mammosomatotroph hyperplasia. N Engl J Med. 323(5):322–326.
5. Zimmerman D, Young WF, Ebersold MJ, et al. 1993 Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab. 76(1):216–222.
6. Gelber SJ, Heffez DS, Donohoue PA. 1992 Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr. 120:931–934.[CrossRef][Medline]
7. Extabe J, Gaztambide S, Latorre P, Vasquez J. 1993 Acromegaly: an epidemiological study. J Endocrinol Invest. 16:181–187.[Medline]
8. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. 1990 Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 71:1427–1433.[Abstract/Free Full Text]
9. Thapar K, Kovacs K, Stefaneanu L, et al. 1997 Overexpression of the growth hormone-releasing hormone gene in acromegaly-associated pituitary tumors. Am J Pathol. 151:769–784.[Abstract]
10. Matsuno A, Katakami H, Sanno N, et al. 1999 Pituitary somatotroph adenoma producing growth hormone (GH)-releasing hormone (GHRH) with an elevated plasma GHRH concentration: a model case for autocrine and paracrine regulation of GH secretion by GHRH. J Clin Endocrinol Metab. 84(9):3241–3247.
11. Asa SL, Ezzat S. 1998 The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev. 19(6):798–827.
12. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 325:1688–1695.[Abstract]
13. Shenker A, Weinstein LS, Moran A, et al. 1993 Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein Gs. J Pediatr. 123:509–518.[CrossRef][Medline]
14. Dotsch J, Kiess W, Hanze J, et al. 1996 Gs mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright symdrome. J Clin Endocrinol Metab. 81(11):3839–3842.
15. Shimon I, Melmed S. 1997 Genetic basis of endocrine disease. Pituitary tumor pathogenesis. J Clin Endocrinol Metab. 82(6):1675–1681.
16. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. 1989 GTPase inhibitng mutations activate the chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. Nature. 40:692–696.
17. Bale AE, Norton JA, Wong EL, et al. 1991 Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res. 51:1154–1157.[Abstract/Free Full Text]
18. Gadelha MR, Prezant TR, Une KN, et al. 1999 Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab. 84(1):249–256.
19. Yamada S, Yoshomoto K, Sano T, et al. 1997 Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 82(1):239–242.
20. Boggild MD, Jenkinson S, Pistorello M, et al. 1994 Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab. 78:387–392.[Abstract]
21. Bates AS, Farrell WE, Bicknell EJ, et al. 1997 Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab. 82(3):818–824.
22. Felix IA, Horvath E, Kovacs K, Smyth HS, Killinger DW, Vale J. 1986 Mammosomatotroph adenoma of the pituitary associated with gigantism and hyperprolactinemia. A morphological study including immunoelectron microscopy. Acta Neuropathol. 71:76–82.[CrossRef][Medline]
23. Asa SL, Scheithouer BW, Bilbao JM, et al. 1984 A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab. 58(2):796–803.
24. Bevin JS, Asa SL, Rossi ML, Esiri MM, Adams CB, Burke CW. 1989 Intrasellar gangliocytoma containing gastrin and growth hormone-releasing hormone associated with a growth hormone-secreting pituitary adenoma. Clin Endocrinol. 30:213–224.[Medline]
25. Araki Y, Sakai N, Andoh T, Yoshimura S, Yamada H. 1992 Central neurocytoma presenting with gigantism: case report. Surg Neurol. 38(2):141–145.
26. Sano T, Asa SL, Kovacs K. 1988 Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev. 9:357–373.[Abstract/Free Full Text]
27. Beuschlein F, Strasburger CJ, Siegerstetter V, Bidlingmaier M, Blum HH, Reincke M. 1999 Ectopic production by a malignant lymphoma causing acromegaly: evidence for auto/paracrine growth. Proc 81st Meeting of The Endocrine Society, San Diego, CA p.143.
28. Duchowny MS, Katz R, Bejar RL. 1984 Hypothalamic mass and gigantism in neurofibromatosis: treatment with bromocriptine. Ann Neurol. 15:302–304.[CrossRef][Medline]
29. Fuqua JS, Berkovitz GD. 1998 Growth hormone excess in a child with neurofibromatosis type I and optic pathway tumor: A patient report. Clin Pediatr. 37:749–752.[Free Full Text]
30. Manski TJ, Haworth CS, Duval-Arnould BJ, Rushing EJ. 1994 Optic pathway glioma infiltrating into somatoststinergic pathways in a young boy with gigantism. J Neurosurg. 81:595–600.[Medline]
31. Palmiter RD, Brinster RL, Hammer RE, et al. 1982 Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature. 300:611–615.[CrossRef][Medline]
32. Hammer RE, Brinster RL, Rosenfeld MG, Evans RM, Mayo KE. 1985 Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature. 315:413–419.[CrossRef][Medline]
33. Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD. 1989 Histopathology assoicated with elevated levels of growth hormone and insulin-like growth factor 1 in transgenic mice. Endocrinology. 124:40–48.[Abstract/Free Full Text]
34. Blumberg DL, Sklar CA, David R, Rothenberg S, Bell J. 1989 Acromegaly in an infant. Pediatrics. 83(6):998–1002.
35. Ezzat S, Orster MJ, Berchtold P, Harris AG. 1994 Acromegaly. Clinical and biochemical features in 500 patients. Medicine. 73:233–240.[Medline]
36. Bates AS, Van’t Hoff W, Jones JM, Clayton RN. 1993 An audit of outcome of treatment in acromegaly. Q J Med. 86:293–299.[Abstract/Free Full Text]
37. Grellier P, Chanson P, Casadevall N, Abboud S, Schaison G. 1996 Remission of polycythemia vera after surgical cure of acromegaly. Ann Intern Med. 124:495–496.[Free Full Text]
38. Koller EA, Green L, Gertner JM, Bost M, Malozowski SN. 1998 Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients. J Clin Endocrinol Metab. 83(7):2380–2383.
39. Barkan AL, Beitins IZ, Kelch RP. 1988 Plasma insulin-like growth factor-1/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 67(1):69–73.
40. Juul A, Bang P, Hertel NT, et al. 1994 Serum insulin-like growth factor I in 1030 healthy children, adolescents and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 78:744–752.[Abstract]
41. Gourmelen M, Le Bouc Y, Girard F, Binoux M. 1984 Serum levels of insulin-like growth factor (IGF) and IGF binding protein in constitutionally tall children and adolescents. J Clin Endocrinol Metab. 59:1197–1203.[Abstract/Free Full Text]
42. Stratakis CA, Mastorakos G, Magiakou MA, et al. 1996 Twenty-four-hour secretion of growth hormone (GH), insulin-like growth factors-1 and 11 (IGF-I, -II), prolactin (PRL) and thyrotropin (TSH) in young adults of normal and tall stature. Endocr Res. 22(3):261–276.
43. Drop SLS, De Waal WJ, De Muinck Keizer-Schrama PF. 1998 Sex steroid treatment of constitutionally tall stature. Endocr Rev. 19(5):540–558.
44. Lecointre C, Toublanc J-E. 1997 Psychological indications for treatment of tall stature in adolescent girls. J Pediatr Endocrinol Metab. 10:529–531.[Medline]
45. Binder G, Grauer ML, Wehnwe AV, Wehner F, Ranke MB. 1997 Outcome in tall stature: final height and psychological aspects in 220 patients with and without treatment. Eur J Pediatr. 156:905–910.[CrossRef][Medline]
46. Lu PW, Silink M, Johnston I, Cowell CT, Jimenez M. 1992 Pituitary gigantism. Arch Dis Child. 67:1039–1041.[Abstract/Free Full Text]
47. Eastman RC, Gorden P, Glatstein E, Roth J. 1992 Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 21:693–712.[Medline]
48. Lamberts SWJ, Reubi JC, Krenning EP. 1992 Somatostatin analogs in the treatment of acromegaly. Endocrinol Metab Clin North Am. 21:737–752.[Medline]
49. Morangi I, De Boisvilliers F, Chanson P, et al. 1994 Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 79:145–151.[Abstract]
50. Drange MR, Melmed S. 1998 Long-acting lantreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab. 83(9):3104–3109.
51. Moran A, Pescovitz OH. 1994 Long-term treatment of gigantism with combination octreotide and bromocriptine in a child with McCune-Albright syndrome. Endocr J. 2:111–113.
52. Jaffe CA, DeMott-Friberg R, Frohman LA, Barkan. 1997 Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. J Clin Endocrinol Metab. 82(2):634–637.
53. Barkin A, Dimaraki E, Besser GM, et al. 1999 Treatment of acromegaly with B2036-PEG, a growth hormone receptor antagonist. Proc 81st Meeting of The Endocrine Society, San Diego, CA, p. 82.

This article has been cited by other articles:

				V. Narayanaswamy, K. R. Rettig, and S. K. Bhowmick Excessive Growth Clinical Pediatrics, September 1, 2008; 47(7): 705 - 710. [Abstract] [PDF]

				M. Misra, J. Cord, R. Prabhakaran, K. K. Miller, and A. Klibanski Growth Hormone Suppression after an Oral Glucose Load in Children J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4623 - 4629. [Abstract] [Full Text] [PDF]

				M Rix, P Laurberg, A S Hoejberg, and B Brock-Jacobsen Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl Eur. J. Endocrinol., August 1, 2005; 153(2): 195 - 201. [Abstract] [Full Text] [PDF]

				M. Misra, K. K. Miller, D. B. Herzog, K. Ramaswamy, A. Aggarwal, C. Almazan, G. Neubauer, J. Breu, and A. Klibanski Growth Hormone and Ghrelin Responses to an Oral Glucose Load in Adolescent Girls with Anorexia Nervosa and Controls J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1605 - 1612. [Abstract] [Full Text] [PDF]

				C. A. Stratakis, L. S. Kirschner, and J. A. Carney Clinical and Molecular Features of the Carney Complex: Diagnostic Criteria and Recommendations for Patient Evaluation J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4041 - 4046. [Abstract] [Full Text] [PDF]

				C. A Stratakis, M. L Turner, A. Lafferty, J. R Toro, S. Hill, J. M Meck, and J. Blancato A syndrome of overgrowth and acromegaloidism with normal growth hormone secretion is associated with chromosome 11 pericentric inversion J. Med. Genet., May 1, 2001; 38(5): 338 - 343. [Full Text]

This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eugster, E. A. Articles by Pescovitz, O. H. Search for Related Content PubMed PubMed Citation Articles by Eugster, E. A. Articles by Pescovitz, O. H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH